ESG Updates: Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB) | Oct 27, 2021 (PDF 0.5 MB) | July 22, 2021 (PDF 1.8 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
For questions about investor relations or the share registry, please contact our team.